Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Cidara Therapeutics (NASDAQ: CDTX).The analyst commented, “We hosted the management ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE